Reducing Fibroblast Persistence in Pulmonary Fibrosis as a Mechanism of Resolution
减少肺纤维化中成纤维细胞的持久性作为解决机制
基本信息
- 批准号:9795882
- 负责人:
- 金额:$ 52.42万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2019
- 资助国家:美国
- 起止时间:2019-08-01 至 2024-07-31
- 项目状态:已结题
- 来源:
- 关键词:AblationAddressAffectAlveolarApoptosisApoptoticAsiaBCL2 geneBlood capillariesCessation of lifeCicatrixCoalCollagenDepositionDevelopmentDiagnosisDiseaseDustEpithelialExposure toExtracellular MatrixFemaleFibroblastsFibrosisFlow CytometryGasesHumanImpairmentInhalationInjuryInterstitial Lung DiseasesInvestigational TherapiesLinkLungLung diseasesMediatingMethodsModelingMolecularMonitorMorbidity - disease rateMusOccupationalOrganOutcomePathway interactionsPatient-Focused OutcomesPatientsPlayPoisonPopulationProcessProteinsPulmonary FibrosisResistanceResolutionRespiratory FailureRiskRisk FactorsRoleSignal TransductionSilicatesSilicon DioxideTestingTherapeuticTherapeutic InterventionTissuesUnited StatesVeteransWorkX-Ray Computed Tomographybasecigarette smokecigarette smokingclinically relevanteffective therapygenetic approachimproved outcomein vivoinhibitor/antagonistinsightknock-downmalemicroCTmortalitynovelnovel therapeuticsoutcome forecastparticlepreventresponsesmall molecule inhibitortargeted treatmenttherapeutic target
项目摘要
Project Summary
Interstitial lung diseases (ILD) include a devastating group of fibrotic parenchymal diseases with high
morbidity and mortality, for which there are limited effective therapies. Pulmonary fibrosis (PF) develops in ILD
patients in response to alveolar epithelial injury and the subsequent activation and accumulation of pro-fibrotic
fibroblasts, which deposit collagen and other extracellular matrix (ECM) components. The accumulation and
persistence of pro-fibrotic fibroblasts and the deposition of ECM leads to progressive fibrosis resulting in
declining gas exchange in the alveolar-capillary units. The inhalation of silicate dust, cigarette smoke and toxic
chemicals are known risk factors for developing fibrotic lung disease and these exposures have
disproportionally affected US veteran's, coal miners and construction workers. PF is generally believed to be
irreversible. Consequently, it becomes increasingly important to identify molecular pathways that are targetable
for therapeutic intervention. This proposal seeks to address this unmet need by investigating the central
hypothesis that the development of pro-fibrotic fibroblast resistance to apoptosis contributes to progressive
fibrotic disease. Furthermore, we propose that expression of the anti-apoptotic gene Bcl-2 plays a central role
in mediating the persistence of pro-fibrotic fibroblasts. Based on robust preliminary studies in a silica-induced
model of pulmonary fibrosis, we propose testing this central hypothesis with 3 specific aims: Specific Aim 1
will test the hypothesis that in vivo ablation of pro-fibrotic lung fibroblasts will induce the resolution of persistent
pulmonary fibrosis initiated by the intratracheal instillation of silica particles. Specific Aim 2 will test the
hypothesis that reducing the resistance to apoptosis in pro-fibrotic fibroblasts promotes the resolution of
progressive pulmonary fibrosis. This hypothesis will be tested using a genetic approach to determine if
conditional deletion of the anti-apoptotic gene Bcl-2 in pro-fibrotic fibroblasts leads to the apoptosis of fibrotic
lung fibroblasts and the resolution of persistent fibrosis in a model of silica-induced pulmonary fibrosis.
Specific Aim 3 will test the hypothesis that clinically relevant Bcl-2 inhibitors will therapeutically target pro-
fibrotic fibroblasts and promote the resolution of established pulmonary fibrosis. This hypothesis will be tested
by treating mice with a small molecule inhibitor to reduce Bcl-2 activity, prevent fibroblast survival and promote
the resolution of persistent fibrosis in vivo. Mice will be followed using micro-CT imaging to monitor disease
development, progression and resolution. The proposed studies will provide new understanding about the
targeting of pro-fibrotic fibroblasts for death and how this may aid in the resolution of fibrosis. Furthermore, the
outcome of this work should significantly impact our understanding of the mechanisms that control the
resolution of fibrosis and its persistence in other organs and tissues.
项目总结
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Elizabeth Frances Redente其他文献
Elizabeth Frances Redente的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Elizabeth Frances Redente', 18)}}的其他基金
Reducing Fibroblast Persistence in Pulmonary Fibrosis as a Mechanism of Resolution
减少肺纤维化中成纤维细胞的持久性作为解决机制
- 批准号:
10451554 - 财政年份:2019
- 资助金额:
$ 52.42万 - 项目类别:
Reducing Fibroblast Persistence in Pulmonary Fibrosis as a Mechanism of Resolution
减少肺纤维化中成纤维细胞的持久性作为解决机制
- 批准号:
10661572 - 财政年份:2019
- 资助金额:
$ 52.42万 - 项目类别:
Reducing Fibroblast Persistence in Pulmonary Fibrosis as a Mechanism of Resolution
减少肺纤维化中成纤维细胞的持久性作为解决机制
- 批准号:
10217236 - 财政年份:2019
- 资助金额:
$ 52.42万 - 项目类别:
Mechanisms of TNF-alpha Mediated Resolution of Pulmonary Fibrosis
TNF-α介导的肺纤维化消退机制
- 批准号:
9056329 - 财政年份:2015
- 资助金额:
$ 52.42万 - 项目类别:
The role TNF-alpha and Macrophages in the Resolution of Pulmonary Fibrosis
TNF-α 和巨噬细胞在解决肺纤维化中的作用
- 批准号:
7752955 - 财政年份:2009
- 资助金额:
$ 52.42万 - 项目类别:
The role TNF-alpha and Macrophages in the Resolution of Pulmonary Fibrosis
TNF-α 和巨噬细胞在解决肺纤维化中的作用
- 批准号:
8137245 - 财政年份:2009
- 资助金额:
$ 52.42万 - 项目类别:
The role TNF-alpha and Macrophages in the Resolution of Pulmonary Fibrosis
TNF-α 和巨噬细胞在解决肺纤维化中的作用
- 批准号:
7930529 - 财政年份:2009
- 资助金额:
$ 52.42万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 52.42万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 52.42万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 52.42万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 52.42万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 52.42万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 52.42万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 52.42万 - 项目类别:
EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 52.42万 - 项目类别:
Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 52.42万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 52.42万 - 项目类别:
Research Grant